– Management will hold a conference call on Thursday, May 2nd at 4:30pm ET/1:30pm PT.
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company that uses PLK1 inhibition to develop novel treatments for a variety of cancers, announced today that , financial results for the first quarter ended March 31, 2024 were announced after the close of trading on Thursday, May 2.
Conference calls and webcasts
Cardiff Oncology will host a conference call and live webcast on May 2, 2024 at 4:30 PM ET/1:30 PM PT. Those wishing to listen to the live conference call can do so using his webcast link in “Investors.” section of his website for the company (https://investors.cardiffoncology.com/news-events/events). After the conference call, a replay will be available on the Investor Relations section of the company's website.
About Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop new treatments for a variety of cancers. The company's flagship asset is onvansertib, a standard of care (SoC) treatment in clinical programs targeting indications including RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC). It is a PLK1 inhibitor being evaluated in combination with The same goes for investigator-initiated trials in small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC). These programs and the company's broader development strategy are designed to target tumor vulnerabilities to overcome therapeutic resistance and deliver superior clinical benefit compared to SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology contact details:
james levin
CFO
858-952-7670
jlevine@cardiffoncology.com
Investor contact information:
Kiki Patel, Pharm.D.
gilmartin group
332-895-3225
Kiki@gilmartinir.com
Media contact:
grace spencer
taft communications
609-583-1151
grace@taftcommunications.com
